The Top 5 Biosimilars Articles for the Week of March 5

March 9, 2018

The Center for Biosimilars recaps the top 5 biosimilars articles for the week of March 5, 2018.

Transcript:

Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of March 5.

Number 5: Michigan has become the latest state to enact legislation governing the pharmacy-level substitution of interchangeable biosimilars.

Number 4: Dr Gillian Woollett, of Avalere Health, told The Center for Biosimilars® that the United States does not have to reinvent the wheel on biosimilar safety, but can learn from international experience.

Number 3: A systematic literature review shows that switching to a biosimilar carries only a low risk of safety concerns or loss of efficacy.

Number 2: Samsung Bioepis’ Ontruzant launched in the United Kingdom this week as the first biosimilar trastuzumab to enter the European market.

Number 1: Dr Scott Gottlieb, Commissioner of the FDA, said in remarks delivered at the National Health Policy Conference of America’s Health Insurance Plans that the economics of biosimilar development in the United States are "currently unstable."

Finally, last week, our e-newsletter asked for your thoughts on whether the FDA should levy fines against research entities that fail to disclose their clinical trial data.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Content:

News | Regulatory | Business | Policy | Practice

x